课题基金 / 基金详情

Inhibition of the Innate Immune Response by the SARS Coronavirus

Inhibition of the Innate Immune Response by the SARS Coronavirus
SARS 冠状病毒对先天免疫反应的抑制
批准号:
7874578
负责人:
Matthew Bryan Frieman
金额:
$10.8万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-07-01 至 2012-05-31

项目摘要

项目成果

Matthew Bryan Frieman的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):严重急性呼吸系统综合症(SARS)是一种潜在的致命疾病,似乎起源于2002年秋季的中国广东省。这种疾病是由一种名为SARS-CoV的新型人类冠状病毒(CoV)引起的。sars冠状病毒是一种高致病性疾病,与其他人类冠状病毒相比死亡率更高。这种增加发病机制的病毒基础尚未确定。我们已经证明sars冠状病毒能够在感染期间调节先天免疫反应。这个应用程序的目的是表征两种新发现的病毒蛋白,我们已经证明能够修改细胞中的干扰素反应。我已经确定了两种病毒编码的蛋白质它们能够阻断干扰素的诱导和细胞中的信号传导。我们将利用细胞生物学和生化技术研究免疫调节蛋白的作用机制。我们将进一步表征SARS蛋白在体内的功能,使用我们的SARS逆向遗传系统,使我们能够删除或突变相关基因,并评估这些突变对SARS感染小鼠模型病毒发病机制的影响。利用新创建的小鼠适应SARS病毒,它不同于SARS的野生型分离株,在小鼠中引起显著的病理和死亡,我们将阐明该病毒的免疫修饰蛋白对疾病病理结果的机制。SARS冠状病毒是研究病毒感染对肺部病理影响的模式生物。确定SARS肺损伤和疾病进展的途径将有助于更好地理解和潜在的新靶点,以对抗全球肺部疾病的负担。在对全球疾病负担进行排名时,世界卫生组织将肺病确定为世界上最普遍的疾病类型,超过了艾滋病毒/艾滋病、腹泻病、疟疾和结核病。确定导致SARS发病和病理的基因和机制可能直接导致其他肺部疾病的更好治疗选择。
英文摘要
DESCRIPTION (provided by applicant): Severe acute respiratory syndrome (SARS) is a potentially fatal disease that appears to have originated in the Guandong Province of China in the fall of 2002. The disease is caused by a new human coronavirus (CoV), named the SARS-CoV. SARS-CoV produces a highly pathogenic disease with increase mortality compared to other human coronaviruses. The viral basis for this increase pathogenesis has not been identified. We have shown that the SARS-CoV is able to modulate the innate immune response during infection. This application aims to characterize two newly identified viral proteins that we have shown are able to modify the Interferon response in cells. I have identified two virally encoded proteins that are able to block Interferon induction and signaling in cells. We will investigate the mechanism of action of the immune modulating proteins using cell biological and biochemical techniques. We will further characterize the function of the SARS proteins in vivo, using our reverse genetic system for SARS which enables us to delete or mutate the genes in question and evaluate the effects of those mutations on viral pathogenesis in a mouse model of SARS infection. Using a newly created mouse adapted SARS virus, which unlike the wild type isolates of SARS, does cause significant pathology and death in mice, we will elucidate the mechanism that immune modifying proteins of the virus have on the pathological outcome of disease. The SARS Coronavirus is a model organism to investigate the effects of virus infection on lung pathology. Identification of the pathway of lung damage and disease progression in SARS will enable better understanding and potential new targets for drugs to combat the worldwide burden of lung diseases. When ranking the global burden of disease, the WHO identifies lung disease as the most prevalent type of disease in the world, outranking HIV/AIDS, diarrheal disease, Malaria and Tuberculosis. Identification of the genes and mechanisms contributing to SARS pathogenesis and pathology may lead directly to better treatment options for other lung diseases.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1186/s12985-014-0209-9
发表时间: 2014-12-07
期刊: Virology journal
影响因子: 4.8
作者: [Matthews K, Schäfer A, Pham A, Frieman M]
通讯作者: Frieman M
DOI: 10.1371/journal.pone.0028479
发表时间: 2011
期刊: PloS one
影响因子: 3.7
作者: [Frieman M, Basu D, Matthews K, Taylor J, Jones G, Pickles R, Baric R, Engel DA]
通讯作者: Engel DA
Coronavirus Challenge Core
  • 批准号:
    10420513
  • 项目类别:
  • 资助金额:
    $144.15万
  • 财政年份:
    2022
  • 负责人:
    Matthew Bryan Frieman
  • 依托单位:
Broad Spectrum Anti-viral Compounds Targeting the SKI Complex
  • 批准号:
    10183158
  • 项目类别:
  • 资助金额:
    $19.31万
  • 财政年份:
    2020
  • 负责人:
    Matthew Bryan Frieman
  • 依托单位:
Role of Diabetes in MERS Coronavirus Pathogenesis
  • 批准号:
    10649491
  • 项目类别:
  • 资助金额:
    $55.08万
  • 财政年份:
    2020
  • 负责人:
    Matthew Bryan Frieman
  • 依托单位:
Role of Diabetes in MERS Coronavirus Pathogenesis
  • 批准号:
    10196973
  • 项目类别:
  • 资助金额:
    $55.69万
  • 财政年份:
    2020
  • 负责人:
    Matthew Bryan Frieman
  • 依托单位:
海外基金